What Is Your Dental Lab Actually Worth? The Seven Valuation Drivers Buyers Use in 2026

A dental lab’s value comes down to seven factors, and revenue is only one of them. Buyers price EBITDA margin, client concentration, owner dependency, digital infrastructure, quality systems, team stability, and market positioning into the multiple they’re willing to pay — and that multiple can swing by a full turn or two depending on how a lab scores across all seven, not just how big the top line is. If you’re only tracking revenue and profit, you’re missing most of what actually determines what your lab is worth.

I spent a good chunk of the last year writing Beyond the Bench, an operational playbook for dental lab owners, and the chapter that surprised me most while researching it wasn’t about production efficiency or case turnaround. It was the one on exit value — because almost none of the owners I talked to had thought about their lab that way before someone else brought it up first.

Why This Is a 2026 Conversation, Not a Someday Conversation

Dental lab M&A went quiet for a few years after the industry’s first big consolidation wave — the one where National Dentex Labs and Dental Services Group rolled up regional players into national platforms, culminating in NDX absorbing DSG outright in 2021. Deal volume peaked that year at 18 transactions, then tapered off.

It’s picking back up. Mergermarket data cited in a June 2026 Dealspeak North America report puts 2026 deal activity at eight transactions so far — nearly matching the 2021 pace — and the buyers look different this time. Apex Dental Laboratory Group took a majority recapitalization from LongueVue Capital and Swaney Group Capital in March. Catalis Dental Lab Partners, backed by Caymus Equity, has been acquiring regional labs — Revolution Dental Lab, JB Dental Lab, and Avaneer Dental Studio among them — and is now among the ten largest lab groups in the country. Centerfield Capital Partners picked up Cap City Dental Lab in 2024 and built it into Dental Alliance Group.

What’s driving the renewed interest is specific, and it matters for how you run your lab whether or not you ever plan to sell. Buyers are chasing technology-enabled, domestically-produced labs over offshore-heavy operations. Jonathan Bluth, a managing director at Brown Gibbons Lang’s healthcare investment banking practice, points to dentists growing frustrated with offshore quality control and the hassle of in-house milling. Consultant Dennis Marvel put it more bluntly in the same report: cheap isn’t always cheap, once you count the remakes.

Digital infrastructure isn’t a nice-to-have on a lab’s spec sheet anymore. It’s a line item in the valuation.

The Seven Valuation Drivers

Here’s the framework from the book, built out of conversations with brokers, buyers, and lab owners who’ve actually been through a transaction. Each driver moves the multiple a buyer applies to EBITDA — some by a little, one or two by a lot.

Two of these deserve more than a row in a table.

Client Concentration Is the One Everyone Underestimates on the Revenue Side

Buyers want to see no single client above 15% of revenue, long relationships, and low churn. Cross that 15% threshold with one or two accounts and you’re not just risking a bad year if that client walks — you’re telling a buyer the business is really a client relationship with a production facility attached, not a durable company. That can knock half a turn to a turn and a half off the multiple. It’s fixable, but it takes two or three years of deliberate diversification, not two or three months.

Owner Dependency Is the One That Actually Determines the Deal

This is the driver that surprises almost every lab owner I’ve talked to, because it’s invisible from the inside. If the lab’s quality, client relationships, and daily operation depend on you personally showing up, a buyer isn’t acquiring a business system. They’re acquiring a risk that gets worse the moment you leave, and they price that risk into the offer — sometimes cutting the multiple by one to two full turns, sometimes making the deal hard to finance at all.

I tell the story in the book of a lab owner who’d run his shop for twenty-three years and treated a broker conversation as a thought experiment — no plans to sell, just curious. The broker came back with a range instead of a number: what the lab was worth as-is, and what it could be worth in three years if he did the work. The gap was $1.4 million, and almost none of it came from growing revenue. It came from getting the business to run without him in the room. Thirty-one months later, he closed a deal at the top of that range, and his attorney told him due diligence took nine weeks instead of the six-month ordeal most owners describe, because every document the buyer asked for already existed.

What to Do About It, Starting Now

You don’t need a term sheet on the table to start acting on this. The lab that’s built to sell well is the same lab that runs well — lower stress, steadier quality, a team that isn’t waiting on one person to make every call. Start with the two highest-leverage moves: get an honest read on what percentage of revenue sits with your top three clients, and get honest about how much of your daily production, client management, and quality control still routes through you personally. Those two numbers will tell you more about your lab’s real value than your last twelve months of collections.

The full seven-driver framework, along with the documentation and preparation timeline that goes with it, is part of the operational playbook I’ve been building for lab owners. More of that is coming to the site.

Related Resources

• How to Value a Dental Practice: What the Number on the LOI Actually Means
• What Is Adjusted EBITDA in a Dental Practice Sale
• Why DSOs Are Flying Blind on Equipment — And What the Smart Ones Are Doing About It
• How Long Does Dental Equipment Actually Last?

Pete Volk is the founder of Dental Strategy Institute and the author of Beyond the Bench, an operational playbook for dental laboratory owners. He has over 25 years of experience in dental equipment manufacturing, DSO strategy, and practice valuation. Susan Volk, RDH, served as contributing clinical reviewer.

For more frameworks, tools, and books like this, explore the full dental strategy resource library at the Dental Strategy Institute.